Aethlon Medical, Inc.

Aethlon Medical, Inc.’s (OTCBB: AEMD) mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to allow the creation of therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Its lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in individuals infected with HIV and hepatitis C virus without the administration of antiviral drugs. Aethlon is focused on advancing its Hemopurifier® as an adjunct to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.

Previous Forums
Date/Time		Forum
Sep 21 2006		Small Cap Investment Conference
Jul 27 2006		Security and Defense On-line Investor Forum
May 17 2006		Robins Emerging Opportunities Investment Conference
Jun 15 2005		Biotechnology / Pharmaceuticals / Healthcare Forum in New York City
Dec 7 2004		Bay Area Biotechnology and Healthcare Forum - Foster City CA
Jul 29 2004		Security and Defense Virtual Forum
Jul 27 2004		Biotechnology/Healthcare Virtual Forum

Market Assistant		PrecisionAlert
Earnings Data Annual Report Press Releases		Enter your email address to receive alerts about this company